drugset / Trial / NCT04304755
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).
Timeline
- Start
- 2021-10-25
- Primary completion
- 2024-01-24
- Completion
- 2024-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |